Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Highlights

  • Highlights
    Selected Articles from This Issue
    Mol Cancer Ther June 1 2020 19 (6) 1219-1219;

Small Molecule Therapeutics

  • Small Molecule Therapeutics
    Novel Dual BET and PLK1 Inhibitor WNY0824 Exerts Potent Antitumor Effects in CRPC by Inhibiting Transcription Factor Function and Inducing Mitotic Abnormality
    Ying Xu, Qianqian Wang, Kunjie Xiao, Zhihao Liu, Lifeng Zhao, Xuejiao Song, Xi Hu, Zhanzhan Feng, Tiantao Gao, Weiqiong Zuo, Jun Zeng, Ningyu Wang and Luoting Yu
    Mol Cancer Ther June 1 2020 19 (6) 1221-1231; DOI:10.1158/1535-7163.MCT-19-0578

  • Small Molecule Therapeutics
    Type I IFN, Ly6C+ cells, and Phagocytes Support Suppression of Peritoneal Carcinomatosis Elicited by a TLR and CLR Agonist Combination
    Allison M. Dyevoich and Karen M. Haas
    Mol Cancer Ther June 1 2020 19 (6) 1232-1242; DOI:10.1158/1535-7163.MCT-19-0885

  • Small Molecule Therapeutics
    A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate
    Ozge Akbulut, Deniz Lengerli, Ozge Saatci, Elif Duman, Urartu O.S. Seker, Aynur Isik, Aytekin Akyol, Burcu Caliskan, Erden Banoglu and Ozgur Sahin
    Mol Cancer Ther June 1 2020 19 (6) 1243-1254; DOI:10.1158/1535-7163.MCT-19-0957

  • Small Molecule Therapeutics
    FGFR Inhibition Enhances Sensitivity to Radiation in Non–Small Cell Lung Cancer
    Gopika SenthilKumar, Michael M. Fisher, Justin H. Skiba, Margot C. Miller, Sean R. Brennan, Saakshi Kaushik, Samantha T. Bradley, Colin A. Longhurst, Darya Buehler, Kwangok P. Nickel, Gopal Iyer, Randall J. Kimple and Andrew M. Baschnagel
    Mol Cancer Ther June 1 2020 19 (6) 1255-1265; DOI:10.1158/1535-7163.MCT-19-0931

  • Small Molecule Therapeutics
    Cabozantinib Reverses Renal Cell Carcinoma–mediated Osteoblast Inhibition in Three-dimensional Coculture In Vitro and Reduces Bone Osteolysis In Vivo
    Tianhong Pan, Mariane Martinez, Kelsea M. Hubka, Jian H. Song, Song-Chang Lin, Guoyu Yu, Yu-Chen Lee, Gary E. Gallick, Shi-Ming Tu, Daniel A. Harrington, Mary C. Farach-Carson, Sue-Hwa Lin and Robert L. Satcher
    Mol Cancer Ther June 1 2020 19 (6) 1266-1278; DOI:10.1158/1535-7163.MCT-19-0174

  • Small Molecule Therapeutics
    CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma
    Ling Zeng, Anatoly Nikolaev, Chuan Xing, Deborah L. Della Manna and Eddy S. Yang
    Mol Cancer Ther June 1 2020 19 (6) 1279-1288; DOI:10.1158/1535-7163.MCT-19-0946

  • Small Molecule Therapeutics
    Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor
    Alfonso García-Valverde, Jordi Rosell, Garazi Serna, Claudia Valverde, Joan Carles, Paolo Nuciforo, Jonathan A. Fletcher, Joaquín Arribas, Oliver Politz and César Serrano
    Mol Cancer Ther June 1 2020 19 (6) 1289-1297; DOI:10.1158/1535-7163.MCT-19-1069

Large Molecule Therapeutics

  • Large Molecule Therapeutics
    Biophysical and Immunological Characterization and In Vivo Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody Pembrolizumab
    Beth Hutchins, Gary C. Starling, Mark A. McCoy, Danuta Herzyk, Frederique M. Poulet, John Dulos, Liming Liu, Soonmo Peter Kang, Laurence Fayadat-Dilman, Mark Hsieh, Christine L. Andrews, Gulesi Ayanoglu, Constance Cullen, Rene de Waal Malefyt, Robert A. Kastelein, Sabine Le Saux, Julie Lee, Sophie Li, Dan Malashock, Svetlana Sadekova, George Soder, Hans van Eenennaam, Aarron Willingham, Ying Yu, Michel Streuli, Gregory J. Carven and Andrea van Elsas
    Mol Cancer Ther June 1 2020 19 (6) 1298-1307; DOI:10.1158/1535-7163.MCT-19-0774

Cancer Biology and Translational Studies

  • Cancer Biology and Translational Studies
    Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy
    Sriram Anbil, Michael Pigula, Huang-Chiao Huang, Srivalleesha Mallidi, Mans Broekgaarden, Yan Baglo, Pushpamali De Silva, Diane M. Simeone, Mari Mino-Kenudson, Edward V. Maytin, Imran Rizvi and Tayyaba Hasan
    Mol Cancer Ther June 1 2020 19 (6) 1308-1319; DOI:10.1158/1535-7163.MCT-19-0791

  • Cancer Biology and Translational Studies
    Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model
    Tomoko Funazo, Takahiro Tsuji, Hiroaki Ozasa, Koh Furugaki, Yasushi Yoshimura, Tetsuya Oguri, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo, Yuichi Sakamori, Hironori Yoshida, Young Hak Kim and Toyohiro Hirai
    Mol Cancer Ther June 1 2020 19 (6) 1320-1327; DOI:10.1158/1535-7163.MCT-19-0649

  • Cancer Biology and Translational Studies
    Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFRY1068 Phosphorylation
    Caroline von Achenbach, Manuela Silginer, Vincent Blot, William A. Weiss and Michael Weller
    Mol Cancer Ther June 1 2020 19 (6) 1328-1339; DOI:10.1158/1535-7163.MCT-19-0609

  • Cancer Biology and Translational Studies
    Gefitinib Inhibits Invasion and Metastasis of Osteosarcoma via Inhibition of Macrophage Receptor Interacting Serine-Threonine Kinase 2
    Caroline Maloney, Michelle P. Kallis, Morris Edelman, Christopher Tzanavaris, Martin Lesser, Samuel Z. Soffer, Marc Symons and Bettie M. Steinberg
    Mol Cancer Ther June 1 2020 19 (6) 1340-1350; DOI:10.1158/1535-7163.MCT-19-0903

  • Cancer Biology and Translational Studies
    A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma
    Nagendra K. Chaturvedi, Matthew J. Kling, Connor N. Griggs, Varun Kesherwani, Mamta Shukla, Erin M. McIntyre, Sutapa Ray, Yutong Liu, Timothy R. McGuire, J. Graham Sharp, Hamid Band, Shantaram S. Joshi and Don W. Coulter
    Mol Cancer Ther June 1 2020 19 (6) 1351-1362; DOI:10.1158/1535-7163.MCT-19-0996

  • Cancer Biology and Translational Studies | AuthorChoice
    Synthetic Lethality with Trifluridine/Tipiracil and Checkpoint Kinase 1 Inhibitor for Esophageal Squamous Cell Carcinoma
    Shinya Ohashi, Osamu Kikuchi, Yukie Nakai, Tomomi Ida, Tomoki Saito, Yuki Kondo, Yoshihiro Yamamoto, Yosuke Mitani, Trang H. Nguyen Vu, Keita Fukuyama, Hiroshi Tsukihara, Norihiko Suzuki and Manabu Muto
    Mol Cancer Ther June 1 2020 19 (6) 1363-1372; DOI:10.1158/1535-7163.MCT-19-0918

  • Cancer Biology and Translational Studies | AuthorChoice
    An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer
    Nancy A. Dawson, Matthew Zibelman, Timothy Lindsay, Rebecca A. Feldman, Michelle Saul, Zoran Gatalica, W. Michael Korn and Elisabeth I. Heath
    Mol Cancer Ther June 1 2020 19 (6) 1373-1382; DOI:10.1158/1535-7163.MCT-19-0531

Back to top
PreviousNext
Molecular Cancer Therapeutics: 19 (6)
June 2020
Volume 19, Issue 6
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

Issue Highlights

  • Biophysical and Immunological Characterization and In Vivo Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody Pembrolizumab
  • Cabozantinib Reverses Renal Cell Carcinoma–mediated Osteoblast Inhibition in Three-dimensional Coculture In Vitro and Reduces Bone Osteolysis In Vivo
  • CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma
  • Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy

Jump to

  • Highlights
  • Small Molecule Therapeutics
  • Large Molecule Therapeutics
  • Cancer Biology and Translational Studies
Advertisement
  • Most Cited
  • Most Read
Loading
  • CD137 Agonist mAb with Reduced Liver Toxicity
  • Truncated BRCA2 Contributes to PARPi Resistance
  • ERPAS to Predict Response to Endocrine Therapy
  • CDK8/19 Inhibitors Enhance NK-Cell–Mediated Cancer Therapy
  • Sialoglycan mAb for Cancer Immunotherapy
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement